Espervita
Espervita Therapeutics is focused on the discovery of metabolic reprogramming therapies for the treatment of cancers in areas with significant unmet medical need, with promising preclinical evidence for the treatment of liver cancer. The company is led by a team with deep expertise in metabolic reprogramming and broad experience in drug discovery and development.
About EspervitaApproach
In order to maintain high rates of proliferation and avoid detection by the immune system, cancer cells alter their metabolism. At Espervita, we have developed a series of new metabolic reprogramming therapies that in preclinical models inhibit cancer cell proliferation, increase immune detection and reduce tumor burden.
ScienceLiver Cancer
Liver cancer is the fastest growing cancer in North America, the fourth most lethal cancer in the world and the only cancer in North America, South America and Central Europe that is increasing in both incidence and mortality. Meanwhile, liver cancer is the third most common cause of cancer-related death in the Asia-Pacific region. The improvement in survival from currently approved systemic therapies is measured only in months, representing a high-priority unmet medical need for an effective systemic therapeutic.
Disease AreasOur Team
Espervita Therapeutics is focused on the discovery of cancer therapies in areas with significant unmet medical need, beginning with liver cancer. The company is led by a team with deep expertise in metabolic reprogramming and broad experience in drug discovery and development.
AboutGet in Touch
For more information about Espervita, please contact us by phone, e-mail, or through our website form.
Contact